Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.37 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.32 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.32 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.32 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.31 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3409861 | 0.88 | PLA2G1B (0.39) | CYP1A2MAPK1PLA2G1BPLA2G2AALDH1A1 | |
| SCHEMBL436979 | 0.88 | PLA2G1B (0.39) | CYP1A2MAPK1PLA2G1BPLA2G2AALDH1A1 | |
| SCHEMBL173217 | 0.86 | CYP1A2 (0.40) | CYP1A2MAPK1PLA2G1BPLA2G2ACA12 | |
| SCHEMBL19543354 | 0.85 | CYP1A2 (0.43) | CYP1A2MAPK1ALDH1A1OPRM1OPRD1 | |
| SCHEMBL13759584 | 0.85 | CYP1A2 (0.43) | CYP1A2MAPK1ALDH1A1OPRM1OPRD1 | |
| SCHEMBL9289906 | 0.83 | CYP1A2 (0.44) | CYP1A2MAPK1PLA2G1BPLA2G2ACA12 | |
| SCHEMBL23192258 | 0.82 | PLA2G1B (0.33) | PLA2G1BPLA2G2AALDH1A1OPRM1OPRD1 | |
| SCHEMBL21016163 | 0.82 | SIGMAR1 (0.44) | CYP1A2MAPK1PLA2G1BPLA2G2ASIGMAR1 | |
| SCHEMBL35704 | 0.82 | CYP1A2 (0.46) | CYP1A2MAPK1PLA2G1BPLA2G2ACA12 | |
| SCHEMBL806005 | 0.82 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10647747-B2 | Cyclosporin derivatives and uses thereof | S&T GLOBAL INC. (US) | 2020-05-12 | — | — | US | disclosed |
| US-20180105558-A1 | NOVEL CYCLOSPORIN DERIVATIVES AND USES THEREOF | S&T GLOBAL INC. | 2018-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10647747-B2 | Cyclosporin derivatives and uses thereof | FKBP5, FKBP1B, MALT1 | CYP1A2 805/4885MAPK1 909/4885PLA2G1B 4676/4885 |
| US-20180105558-A1 | NOVEL CYCLOSPORIN DERIVATIVES AND USES THEREOF | FKBP1B, MALT1, FKBP5 | CYP1A2 1223/4885MAPK1 1050/4885PLA2G1B 4667/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.